

Hull and East Riding Prescribing Committee Minutes – Confirmed

Date / Time	Wednesday 15 th July 2020, 1pm
Venue	Conference Call
Chair	Dr S Raise, GP Prescribing Lead, ER
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician, HUTH
Quorate: Yes / No	Yes

Miss J Morgan, Senior Principal Pharmacist, HUTH
Dr R Schreiber, Medical Secretary, LMC
Ms M Opoku-Fofie, Pharmacist, HFTH
Mr K McCorry, Senior Pharmacist, NECS
Mr A Ramirez, Deputy Chief Pharmacist, HUTH
Dr B Ali, GP Prescribing Lead, Hull
Mrs C Hayward, LPC
Prof A Morice, Professor of Respiratory Medicine, HUTH

Apologies	Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HUTH Mrs E Baggaley, Head of Medicines Service, CHCP Mr P Davis, Strategic Lead Primary Care, Hull, CCG Mrs K Murden, LPC
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2020.07.01	Apologies	As above				
2020.07.02	Declarations of Interest	None				
2020.07.03	Minutes of the Previous Meeting	Accepted as a true record				
2020.07.04	Matters Arising & Action Tracker	<p>RMOC – Heparinised Saline JM will chase</p> <p>Correspondence Received Rheumatology pathway rituximab without MTX – rheumatology specialist pharmacist will discuss with consultant</p> <p>Humber CCG Evidence Based Interventions KMc to discuss wording with commissioners – JM to extend due date as commissioners have not had time to look at due to Covid</p> <p>Correspondence Received RS to discuss SCF with LMC – this was discussed by LMC there are concerns over private care providers using NHS SCF. RS will discuss outside of meeting with Dr Grover – JM to arrange</p> <p>Correspondence Received AR to speak to Dr Grover regarding SCF</p> <p>Minutes WH has amended page 2 of the minutes regarding Sativex</p> <p>Minutes WH has arranged for a WEBEX for this meeting</p> <p>Tracker WH has added Lurasidone to the red list</p> <p>Tracker KMc to add Lurasidone to optimise</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Extend due date</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>		<p>JM</p> <p>JM</p> <p>KMc</p> <p>RS</p> <p>AR</p> <p>WH</p> <p>WH</p> <p>WH</p> <p>WH</p> <p>KMc</p>	<p>1/20</p> <p>1/20</p> <p>11/20</p> <p>7/20</p> <p>7/20</p> <p>7/20</p> <p>7/20</p> <p>7/20</p> <p>7/20</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Tracker JS/DC not at meeting JM will chase wording for lurasidone on formulary</p> <p>Traffic Light Status Selexipag, Brolucizumab, Liposomal Cytarabine and Dinoprostone have been added to red list</p> <p>PG/SCF WH did not add sandostatin SCF to HERPC agenda as no response from consultants received</p> <p>PG/SCF WH has updated website with approved PG/SCF</p>	<p>JS/DC not present to discuss</p> <p>Action complete</p> <p>Unable to add to agenda as not approved by HUTH consultants as yet</p> <p>Action complete</p>		<p>JS/DC</p> <p>WH</p> <p>WH</p> <p>WH</p>	<p>7/20</p> <p>7/20</p> <p>7/20</p> <p>7/20</p>
2020.07.05	Traffic Light Status	<p>Dolutegravir with Lamivudine (Dovato)</p> <p>Lanadelumab TA606 Cemiplimab TA592</p> <p>Gemtuzumab TA545 Liposomal Cytarabine and daunorubicin TA 552 Diphoterine eye irrigating solution – for use within HUTH trust</p>	<p>Approved as red</p> <p>Approved as red Approved as red</p> <p>Approved as red Approved as red Approved as red</p>	WH to update the red list	WH	9/20
2020.07.06	Feedback From Commissioning Groups	All items from April and May that were referred have been approved including the Vitamin B12 bariatric guideline	WH to add to website		WH	9/20
2020.07.07	Prescribing guidelines, shared care frameworks for approval	<p>Safe Prescribing of Vitamin D3 Written as learning exercise in relation to a SI by the trust. Whereby high strength Vitamin D was recommended ONCE a week however due to transcription error was later prescribed and dispensed as ONCE a day in primary care leading to patient suffering hypercalcaemia. Two actions where requested by SI panel for HERPC firstly approval and circulation</p>	CH will circulate to LPC and include in weekly digest a reminder to always check doses		CH	9/20

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>of the bulletin and secondarily to review the HERPC guideline. JM stated she has reviewed the guideline with Dr Aye and Dr Saharia who wish the guideline to remain the same due to the evidence and safety of the licensed once a week dose in primary care. The incident has been discussed with the GP practice although no investigation took place due to Covid and the superintendant of the community pharmacy involved has also been informed.</p> <p>MOK said a similarly incident had happened in her practice last year but was fortunately discovered before given to the patient.</p> <p>HUTH have already shared this learning internally. It was agreed that it would be useful to share externally also.</p> <p>Rhinitis Guideline BA explained it was the first time she had seen guideline and pointed out that the heading needed altering from or to of. BA also said primary care does not perform skin prick tests or IG tests, JM agreed to confirm if this was correct or if it needed to be reworded. In the referral section 1 subsection e it states refer urgently to ENT. BA thought this did not express the seriousness of orbital cellulitis and asked if this could also be reworded to Contact ENT urgently</p>	<p>KMc will add warning to Optimise Rx to check dose</p> <p>JM to follow up with immunology and ENT</p>		<p>KMc</p> <p>JM</p>	<p>9/20</p> <p>9/20</p>
2020.07.08	MHRA DSU	<p>May 2020 New Yellow Card Website Valproate pregnancy screening during pandemic Thalidomide/Lenalidomide/Pomalidomide pregnancy screening during pandemic Letters – Emerade, cyproterone acetate Drug Supply Issues</p> <p>June 2020 Cyproterone acetate:new advice to minimise risk of meningioma</p> <p>DOACs:reminder of bleeding risk, availability of reversal agents Currently Idarucizumab (Praxbind®) reversal agent for Dabigatran on formulary, awaiting publication of NICE TA for Andexanet alfa (Ondexxya®) reversal agent for apixaban and rivaroxaban. As yet there is no licensed reversal agent for Edoxaban</p>	<p>Noted</p> <p>KMc agreed to check for any community patients receiving cyproterone acetate 150mg</p> <p>KMc to check if information has been circulated to Hull and ER CCG</p>		<p>KMc</p> <p>KMc</p>	<p>9/20</p> <p>9/20</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2020.07.09	Regional Medicines Optimisation Committee	None this month				5/20
2020.07.10	Correspondence Received	<p>Issues with SCF LMC have discussed with Humber who are looking at uploading all of SCF JM will look at inviting HUTH HDigital representative to next HERPC to present how SCF will look when sent via Lorenzo</p> <p>Dexamethasone Covid 19 CMO Covid positive patients requiring oxygen therapy should be given dexamethasone, the trust has a protocol which will be discussed at next months D&T meeting. BA asked if a protocol should be used for community? BA was aware CHCP were working on a protocol for dexamethasone therapy in community bedded units. AM emphasised that patients who did not require oxygen therapy would not benefit from dexamethasone therapy and that therefore certain restrictions should be applied</p> <p>NHSE Supply of Additional DOACs Letter advising extra supplies of rivaroxaban and apixaban have been made available in a 20:80 ratio to enable CCGs to switch from warfarin therefore reducing the need for clinic visits during the pandemic</p>	<p>JM to invite HDigital representative to next meeting</p> <p>Noted</p> <p>Noted</p>	<p>No further action</p> <p>No further action</p>	<p>JM</p>	<p>9/20</p> <p>7/20</p> <p>7/20</p>
2020.07.11	Primary Care Rebate Scheme	None to report				7/20
2020.07.12	Additional Minutes for Information	<p>a)MMIG (May)</p> <p>b) HEY D&T (April)</p> <p>c) HTFT DTC</p> <p>d) CHCP</p> <p>e) Formulary Sub Group</p> <p>f) Hull CC Planning & Commissioning</p>	Noted	No further action		7/20
2020.07.13	A.O.B	BA wanted to highlight the need for pregnant BAME women now more than ever to take Vitamin D supplements which can be bought over the contain or obtained using healthy start vouchers where applicable. JM agreed to discuss with obstetrics to find out what is currently in place. MOK agreed this was a good idea but asked that it be emphasised that it	JM to discuss with obstetrics to see what is already in place.		JM	9/20

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>would not be appropriate to request GPs to prescribe.</p> <p>RENEW patients have been admitted to HUTH receiving buprenorphine lyophilisate which is currently not stocked by the trust and has a different bioavailability to Subutex which is the brand the trust currently stocks. JM asked if anyone was aware of this but no one was although it was suggested the switch could have been made as the different formulation would make for a quicker supervision process.</p> <p>JM will discuss with Dr Bassey and Nikki Bush. RENEW need to be aware that patients admitted to HUTH would not be able to receive this preparation.</p>	JM to discuss with Dr Bassey and Nikki Bush.		JM	9/20
	Date and Time of Next Meeting	Wednesday 23 rd September 2020, 1pm, WEBEX				